“We are very proud to have been able to activate this Phase 1 study in record time, particularly given the complexity of a clinical trial assessing a new agent targeting advanced prostate cancer. This new treatment gives hope to patients who have exhausted virtually all available therapeutic options to prolong their lives. We are extremely grateful that one of our patients is the first in the world to benefit from this clinical trial and hope this treatment will prove effective in managing this life-threatening stage of the disease. We thank the patients and their caregivers who are willing to participate in clinical trials because it is the only way to offer new treatment options to patients around the world.”
